The Department of Veterans Affairs covers a narrow set of stem cell treatments that have full FDA approval, primarily bone marrow (hematopoietic stem cell) transplants for blood cancers and related disorders. The broader category of stem cell therapies marketed for joint pain, traumatic brain injury, chronic pain, and similar conditions is generally not covered, because most of those treatments remain unapproved or investigational. Veterans interested in newer stem cell approaches can sometimes access them through VA-sponsored clinical trials, but paying out of pocket at a private clinic and expecting VA reimbursement will almost certainly result in a denied claim.
What the VA Actually Covers Right Now
VA medical centers perform hematopoietic stem cell transplants, commonly called bone marrow transplants, for conditions like leukemia, lymphoma, multiple myeloma, and certain severe blood disorders. These transplants have decades of clinical evidence behind them and carry full FDA approval. If your VA oncologist or hematologist determines you need one, the procedure is covered like any other medically necessary treatment within the VA system. Some VA facilities perform these transplants in-house; others refer veterans to affiliated academic medical centers through community care agreements.
Beyond bone marrow transplants, VA coverage for anything labeled “stem cell therapy” gets thin fast. The treatments you see advertised online or at private clinics for arthritis, back pain, erectile dysfunction, or neurological conditions are almost universally outside what the VA will pay for. The reason is straightforward: the VA follows FDA guidance, and the FDA has not approved these therapies for those uses.
Why Most Regenerative Stem Cell Treatments Are Not Covered
The FDA classifies most stem cell products as biological drugs, meaning they need to go through the same rigorous approval process as any pharmaceutical. A handful of cord blood products have been approved for narrow uses related to blood and immune system disorders, but the injections marketed for knees, shoulders, spines, and neurological conditions have not cleared that bar. The direct-to-consumer stem cell industry in the United States grew rapidly over the past decade, with the number of businesses at least doubling annually between 2009 and 2014, while FDA enforcement in the form of warning letters remained limited.1Future Medicine (Regenerative Medicine). The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis That gap between industry expansion and regulatory oversight matters for veterans, because the VA will not reimburse treatments the FDA considers unapproved.
This creates a frustrating situation. A veteran with chronic knee osteoarthritis or a service-connected shoulder injury might hear enthusiastic testimonials about stem cell injections from private clinics charging $5,000 to $15,000 per treatment. Those clinics operate in a regulatory gray zone, and the VA has no mechanism to cover their services. Even if a veteran pays out of pocket and later seeks reimbursement, the claim will be denied because the treatment is not part of the VA’s standard benefit package and lacks the evidence base the VA requires.
Clinical Trials as an Alternative Path
Veterans who want access to experimental stem cell therapies have a more legitimate route through clinical trials. The VA’s research arm, the Office of Research and Development, funds and participates in studies on regenerative medicine. VA medical centers have been involved in trials exploring stem cell approaches for conditions that disproportionately affect veterans, including traumatic brain injury, spinal cord injury, and post-traumatic stress disorder.
For traumatic brain injury in particular, stem cell-based therapies have shown some promise as a restorative strategy. Current evidence suggests that transplanted cells work less by replacing damaged neurons directly and more through indirect mechanisms like signaling to surrounding cells, modulating the immune response, and supporting vulnerable neural networks. However, clinical translation has been limited by wide variation in cell sources, delivery methods, treatment timing, and how outcomes are measured across different trials.2PubMed Central. Stem Cell Therapy for Traumatic Brain Injury: Translational Mechanisms, Biomarkers, and Clinical Trials That inconsistency is a big part of why no stem cell therapy for TBI has yet reached FDA approval.
Enrolling in a clinical trial through the VA means the experimental treatment itself is provided at no cost to the veteran. Travel and associated care costs are typically covered as well. The trade-off is that trials have strict eligibility criteria, may involve placebo arms, and are available only at specific VA sites. Veterans can search for open trials at ClinicalTrials.gov and filter by VA sponsorship, or ask their VA provider about active studies at their facility.
The VA’s Work With Biologics and PRP
While full-blown stem cell therapies remain investigational for most orthopedic uses, the VA has been more active with related biological treatments like platelet-rich plasma, commonly known as PRP. PRP is not a stem cell product, but it sits in the same broad regenerative medicine space and is sometimes confused with stem cell therapy in marketing materials.
The VA hospital in Palo Alto, California, has established a notable model in this area. A biorepository-linked PRP registry there tracks veterans receiving PRP injections for knee osteoarthritis, collecting patient-reported outcomes before and after treatment alongside banked samples of the administered PRP. Veterans who consent to federally funded research also undergo gait analysis and advanced MRI imaging. The goal is to correlate the protein composition of each patient’s PRP with their clinical outcomes, building a picture of which patients benefit and why.3PubMed Central. Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference
This kind of systematic data collection is exactly what the broader stem cell field lacks. Private clinics selling stem cell injections rarely track long-term outcomes in any rigorous way, and the absence of that data is one reason the FDA and the VA remain cautious. The Palo Alto registry represents the VA contributing to the evidence base that could eventually support or rule out broader coverage of regenerative therapies.
Safety Risks of Going Outside the VA System
Some veterans, frustrated by the VA’s limited coverage, choose to seek stem cell treatments at private clinics and pay out of pocket. This is their right, but the safety record of the unregulated market should give anyone pause. A comprehensive review of reported adverse events found 35 cases of acute or chronic complications or death following administration of unproven stem cell interventions, drawn from both medical literature and media reports. The review concluded that stem cell products not subjected to proper testing, accepted manufacturing standards, and clinical supervision can pose serious risks.4Stem Cells Translational Medicine. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions
The types of harm reported include infections, tumor formation, blindness from retinal injections, spinal cord compression, and in some cases death. These are not theoretical concerns. And the actual number of adverse events is almost certainly higher than what gets reported, because the direct-to-consumer market has no mandatory reporting system. The FDA alone has been unable to adequately address the problem, and adverse events continue to occur in this largely self-regulated marketplace.5PubMed. Adverse events related to unapproved stem cell products and other regenerative interventions: recommendations for more robust regulation of the direct-to-consumer marketplace
Veterans with service-connected disabilities face an additional practical risk. If an unproven stem cell treatment causes harm, the VA may not cover the resulting complications because the original procedure was obtained outside the VA system and was not an approved therapy. You could end up paying for both the treatment and the medical care needed to fix what went wrong.
How to Navigate the VA System if You Are Interested
If you are a veteran considering stem cell therapy, the first step is a conversation with your VA primary care provider or specialist. Be specific about the condition you want treated and the type of stem cell therapy you have heard about. Your provider can tell you whether any relevant clinical trials are open at your facility or within the VA network, and whether any covered treatments with a similar goal already exist for your condition.
For orthopedic issues like knee or hip osteoarthritis, the VA covers a range of conventional treatments including physical therapy, corticosteroid injections, hyaluronic acid injections, and joint replacement surgery. These have established evidence behind them even if they sound less exciting than stem cells. For TBI and neurological conditions, the VA offers specialized rehabilitation programs, and research trials may offer access to experimental approaches.
Be wary of private clinics that specifically market to veterans, especially those that claim VA coverage or suggest that their treatments are “FDA-cleared.” There is a significant difference between FDA-cleared (which often applies to the device or method used to process cells, not the therapy itself) and FDA-approved (which means the treatment has been evaluated for safety and effectiveness for a specific condition). Many clinics exploit that distinction in their marketing. If a clinic’s website uses phrases like “your own cells, so it’s safe” or “no drugs involved,” treat those as red flags rather than reassurances. The source of the cells does not determine safety; the processing, handling, and injection process all introduce risks.
What Could Change in the Future
The VA’s stance on stem cell therapy is not fixed permanently. It tracks FDA decisions, and if the FDA approves a stem cell product for a specific indication, the VA would incorporate it into its formulary or treatment options the same way it adopts any newly approved therapy. Several stem cell products are currently in late-stage clinical trials for conditions like heart failure, spinal cord injury, and graft-versus-host disease. If those trials succeed and lead to approval, veterans would gain access through standard VA care.
Congress has also shown intermittent interest in expanding regenerative medicine access for veterans. Legislative proposals have surfaced periodically that would direct the VA to study or expand access to stem cell treatments, particularly for TBI and musculoskeletal injuries. None have resulted in major policy changes as of now, but the political pressure exists and could accelerate if clinical evidence strengthens.
The broader scientific picture is one of cautious optimism mixed with real uncertainty. For traumatic brain injury, the basic science showing that transplanted cells can support injured neural networks is encouraging, but the lack of standardization across trials makes it hard to know which cell types, doses, and delivery methods actually work.2PubMed Central. Stem Cell Therapy for Traumatic Brain Injury: Translational Mechanisms, Biomarkers, and Clinical Trials For orthopedic applications, the evidence is similarly fragmented. Registries like the one at the Palo Alto VA are trying to bring order to that fragmentation, but the work is slow and methodical by design.
The Direct-to-Consumer Stem Cell Industry and Veterans
Veterans are a particularly targeted demographic for unproven stem cell clinics. Many veterans live with chronic pain, TBI, PTSD, and musculoskeletal injuries from service, and they are understandably eager for treatments that go beyond what the VA currently offers. Some clinics pitch stem cell injections as a way to avoid surgery or reduce reliance on opioids, framing the treatment in terms that resonate deeply with veterans’ lived experience.
The growth of this industry has been striking. By the mid-2010s, roughly 90 to 100 new stem cell business websites were appearing every year in the United States, while FDA enforcement actions remained sparse.1Future Medicine (Regenerative Medicine). The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis That mismatch between market expansion and regulatory enforcement has only grown more relevant as marketing has become more sophisticated. Some clinics now advertise on social media platforms frequented by veteran communities, use veteran testimonials prominently, and even offer military discounts.
None of this changes the underlying science. A treatment that has not been tested in controlled trials and has not earned FDA approval is not made safer or more effective by a discount or a heartfelt testimonial. Veterans considering these options should check whether the clinic is registered with ClinicalTrials.gov, whether the specific product has an active Investigational New Drug application with the FDA, and whether the clinic can provide published peer-reviewed evidence for the specific condition being treated. If the answer to all three is no, the treatment is a gamble with your health and your money, and the VA will not be there to cover the bill if something goes wrong.